FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Metastatic Breast Cancer
Study : Use of cannabis for cancer symptom management
Most relevant for: People with cancer interested in using cannabis to help manage symptoms.
Among people with cancer, interest in the use of cannabis to manage cancer symptoms and treatment side effects is high. The world's leading professional organization of oncologists has published strategies to help adults with cancer and their healthcare providers have open, nonjudgmental discussions about the use of cannabis to manage cancer symptoms. (Posted 9/27/24)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Combining two anti-HER2 drugs improves outcomes more effectively than one
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People with Her2-positive metastatic breast cancer
Combining two anti-HER2 drugs increased the time until cancer returned for people with locally advanced or metastatic HER2-positive breast cancer compared to people who received just one anti-HER2 drug. People whose breast cancer had metastasized to the brain also benefitted from the two combined drugs. (Posted 9/17/24)
Este artículo está disponible en español.
Read MoreRelevance: Medium
Research Timeline: Post Approval
Update : News from the FDA: Updates on breast cancer treatment
Relevance: Medium
Research Timeline: Post Approval
Most relevant for: People with BioZorb markers in breast tissue. People who will have a lumpectomy. People interested in cancer-related podcasts.
The FDA updates the risks of using BioZorb Markers, approves a new imaging drug and shares the Oncology Podcast Series. (Posted 8/16/24)
Este artículo está disponible en español.
Read MoreTopic : Acupressure for cancer symptom relief
Most relevant for: People diagnosed with cancer
Acupressure is a safe treatment that can be used to relieve some symptoms of cancer and side effects of treatment. Light pressure applied to key points on the body may help with fatigue, sleep, nausea and possibly other symptoms as well. (Posted 8/1/24)
Este artículo está disponible en español.
Read MoreRelevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Topic : The drug Enhertu is FDA-approved for any advanced or metastatic HER2-positive tumors
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with advanced HER2-positive cancer
The FDA granted accelerated approval of Enhertu for people with any HER2-positive tumor that is metastatic or cannot be surgically removed. Eligible patients must have had previous treatment such as chemotherapy or hormone therapy. (Posted 7/19/24)
Este artículo está disponible en español.
Read MoreTopic : Experts call for early palliative care for cancer patients
Most relevant for: Cancer patients
People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)
Este artículo está disponible en español.
Read MoreRelevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsStudy : Genetic testing among people with cancer can find mutations that may affect treatment and prevention
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
View Related Clinical TrialsMost relevant for: People diagnosed with cancer who have not yet had genetic testing
Despite national guidelines recommending genetic testing, less than 10 percent of eligible patients had genetic testing within two years after their cancer diagnosis. Among those who had testing, 10-30 percent had an inherited mutation that could affect their medical care. (Posted 3/15/2024)
Este artículo está disponible en español.
Read MoreRelevance: Medium
Update : News from the FDA– new breast cancer treatment, thermography warning and implant screening updates
Relevance: Medium
Most relevant for: People with HR-positive and HER2-negative metastatic breast cancer. People with silicone breast implants. People considering thermography screening
This XRAY review is a summary of FDA breast cancer updates from July to December 2023. This includes a new drug approval and two consumer updates. (Posted 2/21/24)
Este artículo está disponible en español.
Read MoreUpdate : New drug combination for the second treatment of some HR-positive advanced breast cancers
Most relevant for: People with hormone receptor (HR)-positive or HER2-negative breast cancer that has spread outside the breast tissue.
The FDA approved Truqap plus Faslodex for the treatment of metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer that returned or worsened after treatment with hormone therapy. The approval is for treating cancers in people whose tumors had a mutation in one of three genes. For people with one of these mutations, Truqap improved the time until their cancer came back or got worse. (Posted 2/9/24)
Este artículo está disponible en español.
Read MoreRelevance: High
Quality of Writing: Medium-High
Article : Genetic testing and the future of medicine
Relevance: High
Quality of Writing: Medium-High
Most relevant for: People interested in genetic testing.
An article published in Katie Couric Media discusses genetic testing and how it can impact health. The author talked with Dr. Robert Steiner, a doctor who specializes in genetics. He talked about genetic testing and how the results can affect health and change lives. (Posted 9/28/23)
Este artículo está disponible en español.
Read MoreSearch XRAY studies and Articles
This Portal Sponsored By: